GeneDx Holdings Corp.

Key metrics

Financial performance

Over the last 6 fiscal years GeneDx Holdings Corp.'s revenue grew from $196.17M to $427.54M, a compound annual growth rate of 13.9%. Net profit margin expanded from -15.1% to -4.9% over the same period - every figure below comes from the company's audited annual filings.

Key statistics

Latest filings

Browse the full filing history (748 filings)

Recent press releases

• GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference2026-05-26

  GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | GeneDx, LLC

• GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook2026-05-04

  GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook | GeneDx, LLC

• GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 20262026-04-13

  Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .

• Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing2026-03-11

  Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing | GeneDx, LLC

• GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C2026-03-10

  GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C | GeneDx, LLC

Similar companies

The largest companies sharing GeneDx Holdings Corp.'s SEC industry classification (services-health services).